Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University

February 24, 2011 By Bio-Medicine.Org

NEW HAVEN, Conn., Feb. 24, 2011 /PRNewswire/ — Mira Dx
announced today that it has licensed technology from Yale
University based on the acceptance of a pivotal breast cancer study
in the January issue of the journal Cell Cycle. While
numerous BRCA1 coding sequence mutations are associated with
breast cancer risk, such mutations in BRCA1 account for less
than 5% of breast cancer risk. The research identified microRNA
disrupting variants in and around BRCA1 that are polymorphic
in breast cancer populations. One key variant (rs8176318) shows
significant cancer association for predicting the risk of
developing triple negative breast cancer, especially for African
American women.

It is estimated that last year in the US more than 207,090 women
were diagnosed with breast cancer, and that 39,840 women died from
the disease, according to the National Cancer Institute website.
Triple negative breast cancer accounts for 15-20% of all breast
cancers, and is the most deadly form of this disease.

“There is a real need for tools that can help women who have a
family history of breast cancer to better understand their risk,”
said Martin Van Verhoef, President & CEO of Mira Dx. “We are
pleased to continue our advancements in the field of miRNAs in
cancer risk and plan to make this information available to women in
2011 in the form of a new triple negative breast cancer risk test.”
Verhoef continued, “We hope that cancer risk markers such as this
marker will provide valuable information for the tens of thousands
of women and families each year who are and may be affected by
triple negative breast cancer.”

Mira Dx was formed in February 2008 by researchers at Yale
University to discover gene-based laboratory tests conducted on
newly discovered genetic regulators called microRNAs (miRNAs). Mira
Dx is applying miRNA discoveries to develop molecular diagnostics,
which will provide individualized information on the likelihood of
d

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech